Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Yen Hsieh

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Antiviral Research|November 26, 2009
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patientsChia-Yen Dai, Wan-Long Chuang, Ming-Yen Hsieh, et al.
The Kaohsiung Journal of Medical Sciences|February 9, 2012
Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patientsMing-Yen Hsieh, Chia-Yen Dai, Li-Po Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of TreatmentMing-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 30, 2006
Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapyMing-Lung Yu, Wan-Long Chuang, Chia-Yen Dai, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 30, 2006
Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis CChia-Yen Dai, Wan-Long Chuang, Ming-Yen Hsieh, et al.
Antiviral Therapy|February 17, 2007
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapyMing-Lung Yu, Chia-Yen Dai, Li-Po Lee, et al.
Journal of Gastroenterology and Hepatology|March 23, 2007
Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patientsLi-Po Lee, Chia-Yen Dai, Wan-Long Chuang, et al.
Journal of Hepatology|December 26, 2009
Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in TaiwanChia-Yen Dai, Chi-Kung Ho, Jee-Fu Huang, et al.
Hepatology International|November 11, 2010
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patientsChung-Feng Huang, Ming-Yen Hsieh, Jeng-Fu Yang, et al.
The Journal of Infectious Diseases|December 3, 2005
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infectionChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Antiviral Research|November 26, 2009
Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patientsChia-Yen Dai, Wan-Long Chuang, Ming-Yen Hsieh, et al.
The Kaohsiung Journal of Medical Sciences|February 9, 2012
Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patientsMing-Yen Hsieh, Chia-Yen Dai, Li-Po Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of TreatmentMing-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 30, 2006
Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapyMing-Lung Yu, Wan-Long Chuang, Chia-Yen Dai, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|August 30, 2006
Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis CChia-Yen Dai, Wan-Long Chuang, Ming-Yen Hsieh, et al.
Antiviral Therapy|February 17, 2007
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapyMing-Lung Yu, Chia-Yen Dai, Li-Po Lee, et al.
Journal of Gastroenterology and Hepatology|March 23, 2007
Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patientsLi-Po Lee, Chia-Yen Dai, Wan-Long Chuang, et al.
Journal of Hepatology|December 26, 2009
Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in TaiwanChia-Yen Dai, Chi-Kung Ho, Jee-Fu Huang, et al.
Hepatology International|November 11, 2010
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patientsChung-Feng Huang, Ming-Yen Hsieh, Jeng-Fu Yang, et al.
The Journal of Infectious Diseases|December 3, 2005
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infectionChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Pageof 16